Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

2061. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus Vijan S, Hofer T P, Hayward R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening intervals for diabetic retinopathy in patients with Type 2 diabetes mellitus. Type of intervention Screening. Economic study type Cost-utility analysis. Study population Hypothetical patients based on the US population of diabetic patients older than 40 years from the Third National Health and Nutrition

2000 NHS Economic Evaluation Database.

2062. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive insulin therapy for type 2 diabetes in Japan. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of Japanese patients with type 2 diabetes. Setting The setting was a hospital

2000 NHS Economic Evaluation Database.

2063. [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics]

[Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Analisis coste-efectividad de la automonitorizacion de la glucosa sanguinea en diabeticos tipo 2 [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Analisis coste-efectividad de la automonitorizacion de la glucosa sanguinea en diabeticos tipo 2 [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics] Clua Espuny J L, Puig Junoy J, Queralt Tomas M (...) L, Palau Galindo A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The self-monitoring of capillary blood glucose (MBG) by Type 2 diabetes patients using reagent strips was studied. Type of intervention Secondary prevention

2000 NHS Economic Evaluation Database.

2064. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective Full Text available with Trip Pro

The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective Palmer A J, Weiss C, Sendi P P, Neeser K, Brandt A, Singh G, Wenzel H, Spinas G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Management strategies for Type I diabetes. Type of intervention Prevention and treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of newly diagnosed 19 year old patients with Type I diabetes, with no baseline complications. Setting A hospital setting

2000 NHS Economic Evaluation Database.

2065. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost (...) -effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Palmer A J, Sendi P P, Spinas G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of metformin

2000 NHS Economic Evaluation Database.

2066. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes Caro J J, Klittich W S, Raggio G, Kavanagh P L, O'Brien J A, Shomphe L A, Flegel K M, Copley-Merriman C, Sigler C Record Status This is a critical abstract (...) ). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population included a hypothetical cohort of Type 2 diabetic patients who were poorly controlled by maximum doses of sulfonylurea (fasting glucose greater than 7.8 mmol/L or 140 mg/dL). The inclusion criteria specified a glycosylated haemoglobin (HbA1c) level outside the normal range (greater than 5.9%), fasting serum glucose (FSG) greater than 7.8

2000 NHS Economic Evaluation Database.

2067. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) Gray (...) A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive blood glucose control policy in patients with type 2 diabetes. Type of intervention

2000 NHS Economic Evaluation Database.

2068. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated (...) hemoglobin A1c (HbA1c) below 7% is unknown.To assess how often each therapy can achieve the glycemic control target levels set by the American Diabetes Association.Randomized controlled trial conducted between 1977 and 1997. Patients were recruited between 1977 and 1991 and were followed up every 3 months for 3, 6, and 9 years after enrollment.Outpatient diabetes clinics in 15 UK hospitals.A total of 4075 patients newly diagnosed as having type 2 diabetes ranged in age between 25 and 65 years and had

1999 JAMA Controlled trial quality: uncertain

2069. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. (Abstract)

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. In type 2 diabetes mellitus the aetiology of long-term complications is multifactorial. We carried out a randomised trial of stepwise intensive treatment or standard treatment of risk factors in patients with microalbuminuria.In this open, parallel trial patients were allocated standard treatment (n=80) or intensive treatment (n=80). Standard treatment (...) followed up for 3.8 years (0.3). Patients in the intensive group had significantly lower rates of progression to nephropathy (odds ratio 0.27 [95% CI 0-10-0.75]), progression of retinopathy (0.45 [0.21-0.95]), and progression of autonomic neuropathy (0.32 [0.12-0.78]) than those in the standard group.Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy. However, further

1999 Lancet Controlled trial quality: uncertain

2070. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. (Abstract)

Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.

1999 Lancet Controlled trial quality: predicted high

2071. Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. (Abstract)

Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. Recent data suggest a protective role of carotenoids in the development of type 2 diabetes mellitus (DM), possibly via an antioxidant effect, but no randomized trial has directly assessed the efficacy of beta-carotene to prevent DM.To determine whether long-term beta-carotene supplementation reduces the risk of developing type 2 DM.A total of 22, 071 healthy US male physicians aged 40 (...) to 84 years in a randomized, double- blind, placebo-controlled trial, from 1982 to 1995. More than 99% of the participants had complete follow-up (median duration, 12 years).Subjects were randomly assigned to receive beta-carotene (50 mg on alternate days) or placebo.Incidence of type 2 DM.A total of 10, 756 subjects were assigned to beta-carotene and 10, 712 to placebo. Incidence of type 2 DM did not differ between groups: 396 men in the beta-carotene group and 402 men in the placebo group

1999 JAMA Controlled trial quality: predicted high

2072. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - I: prevention

A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - I: prevention A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - I: prevention A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - I: prevention Mason J, O'Keeffe C, McIntosh A, Hutchinson A, Booth A, Young R J Authors' objectives To evaluate the role of preventative strategies in reducing foot ulcers in patients with Type 2 diabetes mellitus, both in the general (...) diabetes. Studies that addressed Type 1 as well as Type 2 diabetes were included. Studies that only included participants with Type 1 diabetes were excluded. Outcomes assessed in the review The a-priori outcome measures considered for the review were not reported. Specific outcome measures reported by included studies were as follows: symptoms, limb function, fundi, blood pressure, weight, blood sugar and urine analysis, mortality, patient seen at least once a year, hospitalisation, HbA or HbA1c (unit

1999 DARE.

2073. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment

A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A Authors' objectives To assess the value of treatments for foot ulcers in patients with Type 2 diabetes mellitus. Searching The following databases were (...) , ketanserin, growth factors, granulocyte-colony stimulating factor and education of patients with foot ulcers. Control therapy included: placebo, alternative antibiotic therapy, gauze moistened in saline, dry sterile gauze or alternative modern dressing, conventional or usual care. Participants included in the review Patients with Type 2 diabetes who have diabetic foot ulcers. Studies that addressed Type 1 as well as Type 2 diabetes were included. Studies that only included participants with Type 1

1999 DARE.

2074. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?

Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Kiberd B A, Jindal K K Record Status (...) population comprised all Pima Indians with type 2 diabetes mellitus. Male patients aged 35 years at diagnosis were used for the baseline cohort. The analysis also considered female patients and older patients (men aged over 55 years, women aged over 60 years). Setting Hospital. The study was carried out in Nova Scotia, Canada. Dates to which data relate Effectiveness data were derived from studies published between 1988 and 1996. Cost data were derived from 1997 sources. The price year was 1995. Source

1999 NHS Economic Evaluation Database.

2075. Home-based management can achieve intensification cost-effectively in Type I diabetes

Home-based management can achieve intensification cost-effectively in Type I diabetes Home-based management can achieve intensification cost-effectively in Type I diabetes Home-based management can achieve intensification cost-effectively in Type I diabetes Dougherty G, Schiffrin A, White D, Soderstrom L, Sufrategui M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) initial and almost all subsequent insulin treatment. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Children with IDDM presenting to the emergency department of a children hospital, who fulfilled the following inclusion criteria: over 2 years of age, no sibling with IDDM, living at home, and living within 1 hour of the hospital. Setting Children's hospital (secondary and tertiary-care paediatric hospital) and community. The economic study was carried

1999 NHS Economic Evaluation Database.

2076. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors Golan L, Birkmeyer J D, Welch H G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment of patients with Type 2 diabetes with angiotensin-converting enzyme (ACE) inhibitors. Type of intervention Screening and treatment. Economic study type Cost-effectiveness analysis. Study population Patients 50 years of age with newly diagnosed Type 2 diabetes mellitus not already receiving

1999 NHS Economic Evaluation Database.

2077. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: a systematic review and meta-analysis

the effect of intensive insulin therapy (IIT) in type 1 diabetes on macrovascular complications. Searching MEDLINE was searched from January 1966 to January 1996. Citation Index, personal files, and bibliographies of all retrieved articles were used to identify further articles. There were no restrictions on language of publication. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of 2 years or more duration. Crossover trials were also considered (...) but none of the trials lasted 2 years or more. Specific interventions included in the review Intensive insulin therapy (IIT) through multiple daily injections (3-4/day) of insulin or subcutaneous insulin pump, and conventional therapy (CT), defined as one or two insulin injections per day. Participants included in the review Adults (18-50 yrs) with type 1 diabetes. Studies involving type 1 diabetic patients after renal transplant were excluded. Outcomes assessed in the review The primary outcome

1999 DARE.

2078. Troglitazone: a review of its use in the management of type 2 diabetes mellitus

Troglitazone: a review of its use in the management of type 2 diabetes mellitus Troglitazone: a review of its use in the management of type 2 diabetes mellitus Troglitazone: a review of its use in the management of type 2 diabetes mellitus Plosker G L, Faulds D Authors' objectives To review the use of troglitazone in the management of type 2 diabetes mellitus. The review included epidemiological, pharmacological and tolerability data in addition to effectiveness data. Searching AdisBase (...) ) or insulin. Comparators included other oral antidiabetic drugs and placebo groups. Participants included in the review Patients with type 2 diabetes mellitus or impaired glucose tolerance. Impaired glucose tolerance was typically defined as fasting plasma or serum glucose (FPG or FSG) levels between 7 and 15mmol/L (126 and 270mg/dl). Most of the trials reported in the review involved patients (aged 40-75yrs) with type 2 diabetes mellitus that was inadequately controlled by diet alone (or by diet

1999 DARE.

2079. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. (Abstract)

A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. Retrospective studies have identified oral sulfonylureas, age, and fasting as major risk factors for hypoglycemia in patients with type 2 diabetes. Sulfonylureas may be withheld from elderly patients out of concern for hypoglycemia.To evaluate the hypoglycemic effects of maximum doses of once-daily second-generation sulfonylureas administered to fasting elderly patients.A prospective (...) , randomized, double-blind clinical trial.The University of New Mexico General Clinical Research Center.Fifty-two sulfonylurea-treated subjects with type 2 diabetes with a mean (SD) age of 65.1 (5.7) years.Subjects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic system (GITS). Each subject participated in three 23-hour fasting studies after the sequential administration of 1 week of placebo and 1 week of 10 mg and 1 week of 20 mg of the assigned sulfonylurea.Occurrence

1998 JAMA Controlled trial quality: uncertain

2080. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. (Abstract)

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. It may therefore increase the efficacy of exogenous insulin in patients with insulin-resistant diabetes mellitus.We studied the effect of troglitazone or placebo in 350 patients with poorly controlled non-insulin-dependent (type 2) diabetes mellitus (...) in patients with type 2 diabetes mellitus.

1998 NEJM Controlled trial quality: uncertain